spacer
home > pmps > winter 2002 > nasal delivery of vaccines
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Nasal Delivery of Vaccines

The nasal delivery of vaccines has recently emerged as an attractive alternative to injection. Nasal vaccination has the advantage that it elicits both local and systemic immune responses. The mucosal immune response is rapid and nasal vaccines may also induce protection in distant mucosal sites. Correct formulation and adequate distribution to the nasal mucosa are, however, essential for efficacy and safety. The complexity of nasal geometry represents a major challenge for efficient intranasal vaccination, and current delivery devices may prove inadequate in meeting future safety and reliability requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Per Gisle Djupesland, Founder, Head of R&D and Chairman of OptiNose AS
Dr Per Gisle Djupesland is Founder, Head of R&D and Chairman of OptiNose AS, a Norwegian R&D company developing devices based on a novel technology for the nasal delivery of drugs and vaccines. Dr Djupesland is a specialist in Otorhinolaryngology.

He has a PhD in Nasal Physiology and Aerodynamics from the University of Oslo and has also been Research Fellow at the University of Toronto, Canada. Dr Djupesland holds a degree in International Health and Tropical Medicine from the University of Pierre and Marie Curie in Paris, France, and has been Project Manager for a large-scale vaccination trial for the Norwegian Armed Forces.

spacer
Dr Per Gisle Djupesland
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

Pharmaceuticals and Healthcare Products

Turkish Cargo

Pharmaceuticals are requiring safe and reliable transportation for being highly temperature sensitive products. Thosepharmaceuticals are; diagnostics, vaccines drugs, sera, plasma, protein clinical trials, biotechnological material, pills and all kind of medicines. Turkish Cargo transports all kind of pharmaceuticals, and has been carrying out its operations of transporting and storing drugs and temperature-sensitive medical supplies successfully and with the experience of 80 years; since 1936.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement